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ABSTRACT
Long non-coding RNAs (lncRNAs) have been implicated in normal cellular 
homeostasis as well as pathophysiological conditions, including cancer. Here we 
performed global gene expression profiling of mammary epithelial cells transformed 
by oncogenic v-Src, and identified a large subset of uncharacterized lncRNAs 
potentially involved in breast cancer development. Specifically, our analysis revealed 
a novel lncRNA, LINC00520 that is upregulated upon ectopic expression of oncogenic 
v-Src, in a manner that is dependent on the transcription factor STAT3. Similarly, 
LINC00520 is also increased in mammary epithelial cells transformed by oncogenic 
PI3K and its expression is decreased upon knockdown of mutant PIK3CA. Additional 
expression profiling highlight that LINC00520 is elevated in a subset of human breast 
carcinomas, with preferential enrichment in the basal-like molecular subtype. ShRNA-
mediated depletion of LINC00520 results in decreased cell migration and loss of 
invasive structures in 3D. RNA sequencing analysis uncovers several genes that are 
differentially expressed upon ectopic expression of LINC00520, a significant subset of 
which are also induced in v-Src-transformed MCF10A cells. Together, these findings 
characterize LINC00520 as a lncRNA that is regulated by oncogenic Src, PIK3CA and 
STAT3, and which may contribute to the molecular etiology of breast cancer.
INTRODUCTION
Cancer is largely driven by genetic alterations, 
which lead to the deregulation of gene networks that 
typically govern normal cellular homeostasis. Recent 
studies have implicated long non-coding RNAs (lncRNAs) 
in a diverse array of human cancers [1-4]. Surprisingly, a 
large number of these non-coding transcripts are found 
in genomic regions that experience frequent mutation 
or somatic copy number alterations [5]. In addition, 
many lncRNAs are transcriptionally regulated by major 
oncogenes and tumor suppressors including c-Myc and 
p53 respectively [6, 7]. 
Gene expression profiling of various disease 
model systems has proven to be a powerful approach for 
identifying candidate lncRNAs implicated in cancer. The 
first cancer-associated lncRNAs to be identified using 
differential expression profiling of prostate tumors and 
normal tissue, were prostate cancer associated 3 (PCA3, 
also called DD3) which is currently used as a biomarker 
for prostate cancer [8, 9], and prostate-specific transcript 
1 (PPCGEM1) which is implicated in androgen receptor 
transcriptional activation [10, 11]. Differential expression 
profiling has also led to the discovery of the nuclear 
lncRNA metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1), as one of the first lncRNAs to be 
     Priority Research Paper
Oncotarget81982www.impactjournals.com/oncotarget
ascribed a role as a potential prognostic biomarker for lung 
cancer survival [12]. 
Collectively, lncRNAs may act in either a tumor 
suppressive or oncogenic capacity to modulate cellular 
phenotypes associated with malignancy [13]. One of 
the best-characterized cancer-associated lncRNAs is 
HOTAIR. This lncRNA acts as a molecular scaffold for 
Polycomb Repressive Complex 2 (PRC2) and Lysine-
Specific Demethylase 1 (LSD1) to facilitate epigenetic 
silencing of specific gene loci and promotes breast cancer 
metastasis [1]. Furthermore, expression of HOTAIR is 
also associated with poor survival [1]. ANRIL is another 
lncRNA implicated in cancer. Expression of this antisense 
non-coding RNA in prostate cancer cells, results in the 
transcriptional repression of the INK4n/ARF/INK4a tumor 
suppressor genes, which regulate cell cycle progression 
and senescence [14]. Similarly, in melanoma cells, RNAi-
mediated knockdown of the highly expressed lncRNA 
SPRY4-IT1 results in defects in cell growth and induction 
of apoptosis [15]. 
In spite of these examples, less than 1% of the 
identified human lncRNAs have been characterized 
[16]. Our understanding of lncRNA biology is far from 
complete and the identification, regulation and functional 
characterization of lncRNAs involved in breast cancer 
pathogenesis may provide novel opportunities for 
differential diagnoses and therapeutic interventions. 
Here we identify the novel lncRNA LINC00520 in 
breast cancer using two independent systems of cellular 
transformation driven by oncogenic v-Src and mutant 
PIK3CA, respectively. We further demonstrate that 
LINC00520 expression is clinically relevant and is 
preferentially associated with basal-like breast cancer. 
We also investigate the transcriptional regulation of 
LINC00520 and provide evidence for its role in breast 
cancer development. 
RESULTS
Identification and transcriptional regulation 
of LINC00520 in a model of Src-induced 
transformation of mammary epithelial cells
In order to assemble a comprehensive list of 
lncRNAs that are potentially implicated in breast cancer, 
we systematically surveyed the transcriptome of a 
well-characterized immortalized mammary epithelial 
MCF10A cell line model containing a tamoxifen-
inducible Src oncoprotein (v-Src). Previous studies 
using this model system have demonstrated that ectopic 
expression of Src results in multiple features associated 
with cellular transformation, including colony formation 
in soft agar, increased migration and invasion and tumor 
formation capability in immunocompromised mice 
[17]. Furthermore, Src-induced transformation has been 
demonstrated to drive an onset of molecular events that 
involve epigenetic alterations leading to changes in gene 
expression networks [17]. 
To explore the transcriptome of MCF10A cells 
upon Src induction, we collected RNA before (T0) and 
after Src induction at 4, 12, and 36 hours (T4,T12,T36) 
and performed RNA-sequencing. Differential expression 
analysis revealed thousands of protein coding genes and 
hundreds of differentially regulated non-coding transcripts 
(Figure 1a). As expected, we observed concordant overlap 
with the transcriptional signature previously defined in 
this system [17]. To identify lncRNAs with oncogenic 
potential we focused on a subset of the ncRNAs whose 
transcript levels are robustly increased upon v-Src 
induction (Figure 1a).
To pare down the number of potential candidates, 
we ordered the transformation-induced lncRNAs by 
fold induction as well as final transcript abundance 
at 36 hours. We reasoned that a potent oncogenic 
lncRNA would display both strong induction AND high 
expression. Topping both criteria was LINC00520, an 
uncharacterized lncRNA that displayed both striking 
induction ( > 30 fold) and abundance of ~ 80 FPKM at 
36 hours (Figure 1b). Consequently, LINC00520 ranked 
in the ~95 percentile of expressed genes which is at the 
high end of both reported lncRNA and coding expression 
regimes. Subsequent analyses on LINC00520 indicates 
that it resides ~112kb from the kinesin receptor KTN1 
and ~ 321kb from the Pellino E3 ubiquitin ligase family 
member 2, PELI2 (Figure 1b). In support of LINC00520 
being an independent transcript, we note that LINC00520 
is transcribed in the opposite direction to either flanking 
gene. In addition, transcript structural analysis reveals that 
LINC00520 undergoes splicing and contains 3-4 exons 
depending on the isoform type (Figure 1b). 
LINC00520 is regulated by STAT3 in Src-
transformed cells
Since the transcription factor signal transducer 
and activator of transcription 3 (STAT3) plays a critical 
role in Src-induced transcriptional responses during 
cellular transformation [17], we analyzed published 
chromatin immunoprecipitation (ChIP) data performed 
in the MCF10A Src-induced cells to determine whether 
STAT3 directly binds to the LINC00520 promoter [18]. An 
enrichment of STAT3 binding to the LINC00520 promoter 
region is observed as early as 4 hours post Src induction, 
with a significant increase at 36 hours. This coincides with 
an increase in LINC00520 transcript levels at this time 
point (Figure 1c). Moreover, depletion of STAT3 with 
siRNA abolishes Src-induced upregulation of LINC00520 
(Figure 1d). Taken together, these data implicate STAT3 
in the transcriptional regulation of LINC00520 during 
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Figure 1: Identification and transcriptional regulation of LINC00520 in a model of Src-induced transformation of 
mammary epithelial cells. a. Heat maps showing subset of protein coding genes and long non-coding RNAs that are differentially 
expressed at 4,12 and 36 hours post Src induction, in MCF10A cells. b. RNA Sequencing, relative expression of LINC00520 at various 
time-points post Src induction in immortalized mammary epithelial MCF10A cells. FPKM, fragments per kilobase of transcript per million 
mapped reads. c. STAT3 ChIP enrichment in MCF10A cells post Src induction, at the LINC00520 locus. d. Expression of LINC00520 
following siRNA-mediated depletion of STAT3 in MCF10A-Src transformed cells. Transcript levels were determined by qRT-PCR and 
normalized to GAPDH. Values represent the average of three technical triplicates.
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cellular transformation of mammary epithelial cells driven 
by oncogenic Src.
LINC00520 is regulated by the PI3K pathway
To investigate if LINC00520 plays a broader role 
in transformation we turned to an orthogonal model using 
MCF10A mammary epithelial cells expressing oncogenic 
mutants of PIK3CA. The PI3K pathway is frequently 
hyperactivated in breast cancer mainly due to recurrent 
somatic mutations in PIK3CA, the gene that encodes the 
p110α catalytic subunit of PI3K, or via loss of the tumor 
suppressor Phosphatase and Tensin Homolog (PTEN) [19]. 
As previously reported, oncogenic PIK3CA (H1047R) 
induces cellular transformation as indicated by the increase 
in colony formation in soft agar compared to wild-type 
PIK3CA (Supplementary Figure 1) [20]. We collected 
gene expression data from PIK3CA (H1047R) MCF10A 
cells and compared this to WT p110α using microarrays 
(Figure 2a). We found that many differentially expressed 
genes in the PIK3CA (H1047R)-expressing cells are also 
differentially expressed in Src-transformed MCF10A 
cells, including LINC00520 (Figure 2b). We verified 
LINC00520 expression using qRT-PCR and again found 
that increased LINC00520 transcript levels are observed 
in MCF10A cells expressing mutant PIK3CA (H1047R) 
relative to wild-type PIK3CA-expressing cells (Figure 
2c). Likewise, a similar upregulation of LINC00520 is 
observed in isogenic MDA-MB-231 cells expressing 
PIK3CA (H1047R) relative to wild-type (Figure 2d). By 
contrast, LINC00520 is downregulated upon depletion of 
PIK3CA in SUM159-PT (mutant PIK3CA H1047L) breast 
cancer cells (Figure 2e). Together these data suggest that 
LINC00520 is regulated downstream of oncogenic PI3K. 
LINC00520 is upregulated in human tumors and 
enriched in basal-like human breast carcinomas
It has been reported that lncRNAs tend to display 
tissue specificity. Therefore, we next examined the 
expression of LINC00520 in a panel of breast cancer 
cell lines with defined genetic alterations and molecular 
subtypes. Interestingly, we find a preferential upregulation 
of LINC00520 in basal-like, triple-negative breast cancer 
cell lines (Figure 3a), many of which display a high 
metastatic potential and poor prognosis.
To better understand this finding, we analyzed 
LINC00520 expression in breast carcinoma clinical 
samples. Using RNA-sequencing data, we found that 
LINC00520 is upregulated in human breast tumors (Figure 
3b) and it is particularly enriched in basal-like and HER2 
intrinsic molecular subtypes (Figure 3c). Furthermore, 
within the basal-like subtype, we found 166 differentially 
expressed genes (of 13, 015 transcripts) in samples with 
high LINC00520 expression (Supplementary Figure 
2). Gene set enrichment analysis (GSEA) (based on a 
pre-ranked gene list using SAM’s d-statistic) revealed 
that the expression of LINC00520 in basal-like breast 
cancer was significantly associated with upregulation 
of 26 of the Broad Institute´s Molecular Signatures 
Database (mSigDB) Hallmark gene sets at a FDR < 5% 
(Supplementary Figure 3), including gene sets related 
to activation of the PI3K/AKT/mTOR pathway and 
epithelial-mesenchymal-transition (EMT) (Figure 3d). 
Consistent with this finding, functional analysis, indicates 
that many of the differentially expressed genes in basal-
like carcinomas of the breast with high LINC00520 
expression were primarily implicated in processes 
involved in cell adhesion, extracellular matrix remodeling, 
and wound healing (Figure 3e) and may therefore provide 
insight into potential roles of LINC00520 in breast cancer.
Depletion of LINC00520 blocks breast cancer cell 
migration
In order to assess the biological role of LINC00520 
in breast cancer, we performed shRNA-mediated loss-
of-function studies in basal-like breast cancer cell lines 
containing endogenous levels of LINC00520. Two 
distinct shRNA constructs, each targeting a distinct exon 
of LINC00520, were cloned (Figure 4a). Approximately 
70-90% silencing efficiency was observed by qRT-PCR 
in all cell lines tested including SUM159-PT cells (Figure 
4b), MCF10A-Src cells (Figure 4f) and MCF10DCIS 
cells (Figure 5a). We then investigated the effects of 
LINC00520 depletion on cell proliferation. We observed 
no significant effects on the proliferation of SUM159-
PT cells upon depletion of LINC00520 (Figure 4c). By 
contrast, depletion of LINC00520 leads to a decrease in 
transwell migration of SUM159-PT cells (Figure 4d) and 
MCF10A-Src transformed cells (Figure 4e). Similarly, 
a reduction of invasive protrusions from MCF10DCIS 
spheroids grown in Matrigel is observed upon depletion 
of LINC00520 (Figure 5b-5c). These data implicate 
LINC00520 in cell migration and invasion. 
Overexpression of LINC00520 results in 
alterations in global gene expression
Based on the above loss-of-function studies, we next 
determined whether ectopic expression of LINC00520 
in parental WT MCF10A cells leads to gene expression 
alterations in cancer-associated genes. MCF10A cells 
were transduced with lentivirus made from a modified 
lentiviral construct designed specifically for the over-
expression of non-coding RNAs [21]. This construct was 
used for the ectopic for expression of either LINC00520 
or a control lncRNA (AC006262.1) that is not expressed 
in either parental MCF10A-Src, or MCF10A PIK3CA 
(H1047R) cells. We compared the expression profiles of 
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Figure 2: LINC00520 is regulated by the PI3K pathway. a. Schematic of MCF10A system used to identify PI3K regulated genes 
involved in transformation. b. Heat map of gene expression values from Src-transformed MCF10A cells for genes that increased (left) or 
decreased (right) by two fold in the mutant PIK3CA-transformed MCF10A cells. Quantitative RT-PCR, showing relative expression of 
LINC00520 in: c. MCF10A cells expressing wild-type PIK3CA (WT) compared to mutant PIK3CA H1047R, d. Isogenic MDA-MB-231 
cells expressing wild-type PIK3CA (WT), and mutant PIK3CA H1047R respectively and e. shRNA-mediated knockdown of PIK3CA in 
SUM159-PT cells. Transcript levels were normalized to GAPDH. Data represents average of three independent experiments ± the SEM. 
Statistical significance was determined using paired Student’s t-test, * p < 0.05, ** p < 0.01, ***p < 0.001. 
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Figure 3: Expression Analysis in Clinical Samples of Human Breast Invasive Carcinoma. a. Relative expression of 
LINC00520 in a panel of breast cancer cell lines, compared to MCF10A cells. Expression was determined by qRT-PCR and normalized to 
GAPDH. Values are representative from three independent experiments. b. Breast carcinoma clinical samples show higher expression of 
LINC00520 compared to matched normal breast samples from TCGA dataset (n = 105). c. In breast carcinoma clinical samples (n = 741) 
LINC00520 expression level differs according to the intrinsic molecular subtype. RPKM, reads per kilobase of transcript per million mapped 
reads. d. Gene Set Enrichment analysis (GSEA) of basal carcinomas with high expression of LINC00520. Four of the most associated gene 
sets, of the 50 Hallmark gene sets of the Broad Institute’s MSigDB collection, 11 gene set S were significantly upregulated at an FDR < 
1% and 26 at an FDR < 5% using Hallmark gene set collection. e. Top-ranked Functional Gene Ontology Biological Process and KEGG 
Pathway terms using DAVID. All represented terms were associated with the transcriptomic signature of basal breast carcinomas with high 
LINC00520 expression (Benjamini Hochberg p-value of < 0.05).
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Figure 4: Depletion of LINC00520 blocks breast cancer cell migration. a. Schematic showing regions targeted by LINC00520 
shRNA#1 and shRNA#2. b. Validation of downregulation of LINC00520 in SUM159-PT cells used for proliferation and migration 
assays. c. Proliferation assay using SUM159-PT cells expressing two different LINC00520 shRNA constructs. Data represents average of 
two biological replicates. d. Transwell migration assay of SUM159-PT cells expressing two different LINC00520 shRNA constructs. e. 
Transwell migration assay of MCF10A-Src inducible cells expressing two different LINC00520 shRNA constructs. Cells were induced with 
vehicle (ethanol) or Tamoxifen for 48hours prior to migration. f. Validation of downregulation of LINC00520 in MCF10A-Src inducible 
cells used for migration assays. Data represents average of three biological replicates ± the SEM. Statistical significance was determined 
using unpaired Student’s t test, * p < 0.05, *** p < 0.001. 
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untransduced to transduced cells 72 hours post infection 
using RNA-seq. Using Cuffdiff2 for differential gene 
expression analysis we first established that LINC00520 
was induced upon transduction (~500 fold) and then 
found that 1,898 genes changed significantly in response 
to transduction with LINC00520. To determine if 
LINC00520 might have a regulatory role in transformation 
we next asked if the upregulated genes during MCF10A-
Src transformation were enriched in the genes induced by 
LINC00520 transduction (976 out of the 1,898). We tested 
Figure 5: Depletion of LINC00520 affects the integrity of invasive protrusions. a. Quantitative RT-PCR validation of silencing 
of LINC00520 in MCF10DCIS cells. Transcript levels were normalized to GAPDH and fold change was calculated relative to scrambled 
shRNA #1. b. Representative phase-contrast images of MCF10DCIS acini infected with lentiviral scrambled or LINC00520 shRNA grown 
in 3D Matrigel. Images displayed were taken on day 5. c. Morphological effects of silencing of LINC00520 in MCF10DCIS cells grown in 
(Top) 2D, scale bar = 100μm and (Bottom) in 3D Matrigel cultures. For 3D, images shown were taken at day 5, scale bar = 500μm. 
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for the enrichment of upregulated genes from each time 
point using the hypergeometric test (4,12, and 36 hours) 
and found significant overlap with LINC00520 induction 
signature for all time points (at 4 hours p < 1e-20, at 12 
hours p < 8e-38 and at 36 hours p < 0.008). The most 
significant overlap was found not at the time point with 
the highest LINC00520 expression (36 hours) but at 12 
hours where LINC00520 expression begins to ramp up in 
Figure 6: Heat map showing expression profile of MCF10A cells expressing LINC00520. a. All genes (1693 genes) depicted 
in the heat map are upregulated in MCF10A-Src transformed cells. Abbreviations: UTC - Untransformed MCF10A cells; AC006262.6 is 
a lncRNAs that is not involved in transformation (negative control). Scale bar shows log2 row median centered expression values. b. GO 
analysis of a subset of genes that are upregulated upon ectopic expression of LINC00520 in MCF10A cells (grey line in heat map denotes 
top 291 genes used for analysis).
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the MCF10A-Src time course (Figure 6a). A minority of 
the 12-hour MCF10A-Src up-regulated gene set is down 
regulated in response to LINC00520 overexpression. 
However most of the changes in either direction with 
respect to the untransfected control are not observed in 
the control lncRNA transduction. Interestingly, a subset of 
these LINC00520-upregulated genes have been linked to 
cell migration and invasion among other cellular functions 
(Figure 6b, Supplementary Figure 4). This analysis is 
consistent with the findings that LINC00520 modulates 
cell migration in breast cancer cell lines, a phenotype that 
is recapitulated in v-Src-transformed cells. 
DISCUSSION
Here we identify and describe a novel lncRNA, 
LINC00520, and provide evidence for a potential role in 
breast cancer. LINC00520 is transcriptionally upregulated 
in immortalized mammary epithelial cells transformed by 
oncogenic Src or oncogenic PI3K. We also show that the 
transcription factor STAT3 is critically required for the 
regulation of LINC00520 expression. Notably, expression 
of LINC00520 is increased in basal-like breast cancer 
cells, which also show a preferential increase in STAT3 
activity. Thousands of lncRNAs have been annotated 
to date yet the biological significance of the majority of 
these lncRNAs remains unclear. In this study, we provide 
evidence for a role for LINC00520 in breast cancer. 
Both loss-of-function and gain-of-function approaches 
point to a role for LINC00520 in cell migration and cell 
invasiveness, arguing against the notion that LINC00520 
represents a trivial, promiscuous transcript. 
To date, no orthologs of LINC00520 have been 
described in other mammalian species. This is not 
unexpected, since most lncRNAs appear to be poorly 
conserved and tend to undergo rapid evolution. For 
instance, only approximately 12% of human and mouse 
lncRNAs have orthologs in other species [22, 23] and 
less than 6% of zebrafish lncRNAs share homologous 
sequences in humans or mice [24]. While this lack of 
conservation may suggest lncRNAs are merely cryptic 
noise in the genome, the characterization of Xist 
challenges this notion. Although Xist is critical for dosage 
compensation, most of its sequence is poorly conserved 
and deletion of exon 4, which shows the most convincing 
evidence for conservation, has no functional consequence 
[25]. A more comprehensive catalog of lncRNAs from 
several vertebrate species along with advancements in 
computational assessment tools may improve comparative 
lncRNA studies.  
Our study also demonstrates that LINC00520 affects 
global gene expression. Importantly, ectopic expression 
of LINC00520 results in a transcriptional profile that 
shows significant overlap with that generated by Src-
transformed cells. LINC00520 might mediate its function 
by interacting with various chromatin modifiers and/or 
transcriptional regulators, as observed for lncRNAs such 
as HOTAIR, HOTTIP, MISTRAL and Xist [24, 26-28]. 
Despite these examples, it is still unclear whether these 
RNA-protein interactions are direct. Furthermore, the 
factors that dictate the specificity of these interactions 
have not been clearly defined. Regardless, future work 
will determine the mechanistic action of LINC00520. 
While there are well-studied examples of lncRNAs that 
are enriched in the nucleus [29-31], many lncRNAs 
appear to be cytoplasmic [32-34]. It will be interesting to 
determine the cellular localization of LINC00520, whether 
it undergoes any re-localization to various intracellular 
compartments and how it evades RNA decay. 
Despite the definition of lncRNAs as noncoding, 
nearly half of the expressed lncRNAs encode peptides 
that are actually translated [35]. Ribosome profiling in 
ER-Src cells [35] reveals that non-overlapping regions of 
LINC00520 RNA are translated into 4 peptides (26, 32, 32, 
and 40 amino acids) that are conserved in monkeys but not 
in more evolutionary distant species. The stabilities and 
hence steady-state levels of these peptides are unknown, 
and whether one or more of these peptides are biologically 
functional remains to be determined.
In summary, this study supports the accumulating 
evidence that lncRNAs may function to modulate human 
cancer pathogenesis. It points to a role for lncRNAs in the 
mechanism of action of critical oncogenes, namely Src, 
PI3K and STAT3. To our knowledge, this is the first study 
that investigates the regulation and biological function of 
LINC00520. It also implicates the first lncRNA identified 
as a downstream effector of the PI3K pathway. Future 
studies will dissect the entire complement of LINC00520 
biology and its significance in processes critical for breast 
cancer initiation and progression. 
MATERIALS AND METHODS
Antibodies, plasmids and reagents
pBabe puro HA PIK3CA WT (Addgene plasmid 
#12522) and pBabe puro HA PIK3CA H1047R (Addgene 
plasmid #12524) was a gift from Dr. Jean Zhao. pBABE-
puro was a gift from Hartmut Land, Jay Morgenstern and 
Robert Weinberg (Addgene plasmid #1764). Isogenic 
MDA-MB-231 cells expressing PIK3CA WT, PIK3CA 
E545K and PIK3CA H1047R were a kind gift from Dr. 
Jonathan Backer, and have been described [36]. 
Retroviral expression of LINC00520
LINC00520 was cloned as described previously 
[21]. 
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RNA interference
For LINC00520 and PIK3CA shRNAs, single-
stranded oligonucleotides sense and antisense pairs, 
encoding the indicated target sequences were synthesized 
and cloned into PLKO.1 vector. Stable cell lines were 
maintained in 2μg/ml puromycin. 
PIK3CA shRNA#1, sense, 
5’-CCGGGCACAATCCATGAACAGCATTCGAGAATG 
CTGTTCATGGATTGTGCTTTTTTG-3’;
PIK3CA shRNA#1, antisense, 
5’-AATTCAAAAACACAATCCATGAACAGCATTCTC 
GAGAATGCTGTTCATGGATTGTG-3’
PIK3CA shRNA#2, sense, 
5’-CCGGGCATTAGAATTTACAGCAAGACTCGAGT 
CTTGCTGTAAATTCTAATGCTTTTTTG-3’;
PIK3CA shRNA#2, antisense, 
5’-AATTCAAAAAGCATTAGAATTTACAGCAAGACT 
CGAGTCTTGCTGTAAATTCTAATGC-3’
LINC00520 shRNA#1, sense, 5’- 
ccggAAGAGAAAAGCTGAAGGACACctcgag 
GTGTCCTTCAGCTTTTCTCTTtttttg
LINC00520 shRNA#1, antisense, 5’- 
ccggAAGAGAAAAGCTGAGAAGGACACctcgagGT 
GTCCTTCAGCTTTTCTCTT
LINC00520 shRNA#2, sense, 5’ - 
ccggACCTCAAATCTTTCGAGAACActcgagTGTTCT 
CGAAAGATTTGAGGTtttttg
LINC00520 shRNA#2, antisense, 5’- 
AATTCAAAAAACCTCAAATCTTTCGAGAACActcg 
agTGTTCTCGAAAGATTTGAGGT
Cell culture and immunoblotting
MCF10A and MCF10DCIS.com [37] cells were 
cultured in Ham’s F12/DMEM (Cellgro) supplemented 
with 5% equine serum (Cellgro), 500ng/ml hydrocortisone 
(Sigma-Aldrich), 100ng/ml cholera toxin (List Biological 
Laboratories), 20ng/ml EGF (R&D Systems) and 10ug/
ml insulin. SKBR3 cells were maintained in 10% FBS/
McCoy’s (Cellgro). MCF7, and MDA-MB-468, MDA-
MB-453, MDA-MB-231 cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM; Cellgro) 
supplemented with 10% Fetal Bovine Serum (FBS; 
Cyclone). T47D and BT549 cells were cultured in 10% 
FBS/DMEM, supplemented with 1mg/ml insulin (Sigma-
Aldrich). SUM159-PT cells were grown in Ham’s F12 
medium (Cellgro) supplemented with 5% FBS, 1ug/
ml hydrocortisone (Sigma-Aldrich) and 5ug/ml insulin 
(Sigma-Aldrich). ZR75-1 and HCC1806 were maintained 
in RPMI 1640 supplemented with 10% FBS (Cellgro). 
MCF10A-Src inducible cell lines were cultured as 
previously described [17]. For all western blotting, cells 
were lysed in RIPA buffer with protease and phosphatase 
inhibitors. 
3D Morphogenesis assay
MCF10DCIS cells were grown in three dimensional 
Matrigel cultures as described [38]. Briefly, 3x103 cells 
were suspended in modified growth medium containing 
2% growth factor-reduced Matrigel, 2% Horse serum 
(Cellgro) and 5ng/ml EGF (R&D systems). Cell mixture 
was plated on top of a solidified layer of growth factor-
reduced Matrigel. Cells were fed every 4 days. Phase 
contrast images were acquired using the Nikon Eclipse Ti 
microscope.
Quantitative real-time RT PCR
Total RNA was isolated using the RNeasy kit 
following the manufacturer’s instructions (Qiagen). 
Reverse transcription was performed using Quantitect 
Reverse transcription kit according to the manufacturer’s 
instructions (Qiagen). Quantitative real-time RT-PCR was 
performed using SYBR Green PCR Master Mix (BioRad) 
and the ABI Prism 7900 sequence detector (Applied 
Biosystems). Relative mRNA expression was calculated 
by the ΔΔCT method with GAPDH as reference. Primer 
sequences:
LINC00520 sense: 5’- GTGTACATTTCTGG 
GTAGCTT
LINC00520 antisense: 5’ - AAAGGAAAACAATA 
CAGGCTTG
GAPDH sense: 5’ - GCAAATTCCATGGCACCGT
GAPDH antisense: 5’- TCGCCCCACTT 
GATTTTGG
Transwell migration assay
Transwell migration assay using SUM159-PT 
cells was performed as previously described [39]. Cells 
were allowed to migrate through an 8μm-pore transwell 
(Corning) for 16 hours and NIH3T3 conditioned media 
was used as a chemoattractant in the lower chamber. 
MCF10A-Src-Hygro inducible cells containing 
LINC00520 shRNA constructs were first treated with 
1μM Tamoxifen or ethanol (vehicle) for 48 hours prior to 
migration. Cells were then serum starved and then allowed 
to migrate for 16 hours using MCF10A growth media as 
the chemoattractant. MCF10A-Src-Hygro inducible cell 
lines were generated using a retroviral pLHCX vector 
(Clontech) containing an ER-Src inducible gene. Stable 
cell lines were established after selection with 150μg/ml 
hygromycin for 5 days and maintained thereafter in 50μg/
ml. 
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RNA-Seq analysis and ChIP-Seq analysis
RNA whole transcriptome sequencing (RNA-
seq) was carried out at 0 (1 replicate), 4 (2 replicates), 
12 (1 replicate) and 36hrs (2 replicates) post tamoxifen 
treatment on polyA selected RNA using Illumina tru-seq 
library construction. RNA-seq was also carried out for the 
over-expression experiments in parental MCF10A cells 
that were untransduced (3 replicates), transduced with 
LINC00520 (2 replicates) or transduced with a control 
lincRNA AC006262.6 (2 replicates) on polyA selected 
RNA using Illumina tru-seq library construction harvested 
72 hours post transduction.
Transcript levels were quantified and differentially 
expressed genes were called using cuffdiff2 [40]. Relative 
transcript levels are expressed as a “Fragments Per 
Kilobase of transcript per Million mapped” (FPKM) which 
corrects for the length of the transcript and the depth of the 
libraries. Raw and processed ChIP-Seq data was retrieved 
from [18].
Expression analysis in clinical samples of human 
breast invasive carcinoma
Genomic alterations associated with LINC00520 
were identified by querying genomic data from Breast 
Invasive Carcinomas dataset of TCGA. Data from 
850 breast cancer cases were retrieved from the TCGA 
database (http://cancergenome.nih.gov/), including 
RNAseq gene expression (Illumina HiSeq RNASeqV2 
Level 3.1.9.0) and lncRNA expression from TANRIC 
database (http://bioinformatics.mdanderson.org/main/
TANRIC:Overview). Intrinsic molecular subtype data was 
obtained by applying the PAM50 algorithm to the RNA-
seq data. 
LINC00520 expression level was compared in 
normal-tumor paired samples (n = 105) using a T-test for 
paired samples and compared using One-way ANOVA 
(with unequal variance) in carcinoma samples (n = 741) 
by intrinsic molecular subtypes. Afterwards, LINC00520 
expression levels were dichotomized into low and high 
expression categories using univariate clustering based on 
finite normal mixture modeling (mclust 5.1 package, R 
3.2.2). Differential gene expression was performed using 
two-class unpaired significance of microarray analysis 
(SAM 2.0 package, R 3.2.2) [41] in basal carcinomas 
previously classified with low (n = 96) and high (n = 
30) expression of LINC00520. Next, we performed 
a pre-ranked GSEA (Gene-Set Enrichment Analysis) 
using software provided by the Broad Institute (http://
www.broadinstitute.org/gsea/msigdb/annotate.jsp) on 
a gene list ranked based on the d-statistic computed 
from the LINC00520 differential expression analysis, 
and we assessed enrichment using the Broad Institute´s 
Molecular Signatures Database (mSigDB) Hallmark 
gene sets collection (n = 50) (http://www.broadinstitute.
org/gsea/msigdb/). Finally, functional annotation for the 
transcriptomic signature of basal-like high LINC00520 
expression carcinomas was performed using Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) 6.7 [42]. Gene set enrichments were assessed 
using Gene Ontology Biological Pathway and KEGG 
Pathways summarized version with 13,015 genes (total 
genes in RNASeqV2 data) as background list and gene 
sets containing a minimum of 15 genes. Statistical 
significance was considered when p-value was < 0.05 or 
false discovery rate (FDR) was < 0.05.
Sulforhodamine B (SRB) proliferation assay
For proliferation assay 0.01 x 10^6 cells were 
seeded in complete growth media. Relative number of 
adherent cells at day 0 (~16hrs post-seeding), days 1, 3, 
and 4, were assessed using sulforhodamine B assay as 
previously described [43]. Briefly, adherent cells were 
fixed with 12.5% (w/v) trichloroacetic acid for 1 hour at 
4°C. Cells were then rinsed three times with water and 
stained with a solution of 0.5% (w/v) SRB in 1% acetic 
acid for at least 30 minutes at room temperature. Cells 
were then washed three times with 1% acetic acid and 
allowed to dry. SRB was dissolved in 10 mmol/l Tris (pH 
10.5). Absorbance of solubilized SRB was measured at 
510 nm.
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